European Journal of Health Economics

Article	Citations
Education and medication use later in life and the role of intelligence	83
Beyond 10-year lead-times in EQ-5D-5L: leveraging alternative lead-times in willingness-to-accept questions to capture preferences for worse-than-dead states and their implication	72
Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries	56
Correction to: Geographic distribution of physicians in Portugal	40
Costing methodologies in European economic evaluation guidelines: commonalities and divergences	33
The hidden cost of sophistication: economic complexity and obesity	28
Comparing the measurement properties of the EQ-5D-Y-3L, EQ-5D-Y-5L and CHU9D in children and adolescents: a measurement property study	27
Cost-effectiveness of transcatheter aortic valve implantation in patients at low surgical risk in France: a model-based analysis of the Evolut LR trial	26
Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland	25
Patient-level cost analysis of subfertility pathways in the Dutch healthcare system	24
Psychometric properties and general population reference values for PROMIS Global Health in Hungary	23
Pragmatic randomized controlled trial comparing a complex telemedicine-based intervention with usual care in patients with chronic conditions	23
From test to rest: evaluating socioeconomic differences along the COVID-19 care pathway in the Netherlands	21
Workload and short sickness absences in a cohort of Finnish hospital employees	21
Should Scotland provide genome-wide sequencing for the diagnosis of rare developmental disorders? A cost-effectiveness analysis	21
Expensive today but cheaper tomorrow: lifetime costs of an active middle ear implant compared to alternative treatment options	20
Primary care services and emergency department visits in blended fee-for-service and blended capitation models: evidence from Ontario, Canada	19
Prescription opioids and economic hardship in France	19
Cost awareness among intensivists in their daily clinical practice: a prospective multicentre study	19
Nothing about us, without us? A reflection on and call for involving children in the process of valuing child health	19
Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan	19
Replay to: Comparison of EQ-5D-5 L and EORTC QLU-C10D utilities in gastric cancer patients	18
Comparing EQ-5D-5L and SF-6Dv2 utilities with QLU-C10D utilities in hematologic cancer patients	18
Setting incentives right with long-term risk adjustment	18
Health-related quality of life in patients with alcohol use disorder: comparing instruments and mapping from clinical measures to preference-based measures	18

The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands	17
Economic assessment of abemaciclib for the adjuvant treatment of luminal HER2- breast cancer from the perspective of the Spanish health system	17
Informing decisions in light of parameter uncertainty – an economic evaluation of the adjuvanted recombinant herpes zoster vaccine in Sweden	17
Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma	17
Trends in NICE technology appraisals of non-small cell lung cancer drugs over the last decade	17
The causal effect of catastrophic health expenditure on poverty in Poland	16
On spillovers in economic evaluations: definition, mapping review and research agenda	16
Breaking the rules: decision-making under absolute resource constraints	15
Generating EQ-5D-5L health utility scores from BASDAI and BASFI: a mapping study in patients with axial spondyloarthritis using longitudinal UK registry data	15
How perceptions of bone marrow donation costs affect donation behavior: survey evidence from a large donor registry	15
Hospital resource utilisation from HPV-related diseases in England: a real-world cost analysis	15
Sex differences in care complexity and cost of cardiac-related procedures as a basis for improving hospital payments systems	15
The trade-off between health system resiliency and efficiency: evidence from COVID-19 in European regions	15
Analyzing nurses’ decisions to leave their profession—a duration analysis	15
Benefits beyond health in the willingness to pay for a quality-adjusted life-year	15
Do EQ-5D-Y-3L value sets have common properties, and how do they compare to EQ-5D-5L value sets?	15
Can competition improve hospital quality of care? A difference-in-differences approach to evaluate the effect of increasing quality transparency on hospital quality	15
Correction: AOTMiT reimbursement recommendations compared to other HTA agencies	15
Antivirals to prepare for surges in influenza cases: an economic evaluation of baloxavir marboxil for the Netherlands	15
Costs attributable to hypercholesterolemia in a single period and over the life cycle	14
Estimating loss in capability wellbeing in the first year of the COVID-19 pandemic: a cross-sectional study of the general adult population in the UK, Australia and the Netherlands	14
The impact on quality of life of diet restrictions and disease symptoms associated with phenylketonuria: a time trade-off and discrete choice experiment study	14
The goal of risk equalization in regulated competitive health insurance markets	14
A principled approach to non-discrimination in cost-effectiveness	14
The impacts of working from home on individual health and well-being	13
Economic value of diastasis repair with the use of mesh compared to no intervention in Italy	12
The social value of gambling: surplus estimates by gambling types for France	12
The impact of ambulatory care spending, continuity and processes of care on ambulatory care sensitive hospitalizations	12
Time value of informal care of people with alzheimer’s disease in Spain: a population-based analysis	12
Adverse selection and consumer inertia: empirical evidence from the Dutch health insurance market	12
Is ultra-hypo-fractionated radiotherapy more cost-effective relative to conventional fractionation in treatment of prostate cancer? A cost–utility analysis alongside a randomized HYPO-RT-PC trial	12
Does prescribing apixaban or rivaroxaban versus warfarin for patients diagnosed with atrial fibrillation save health system costs? A multivalued treatment effects analysis	11
Modeling European health systems: an ideal chain of services	11
Valuation of the EQ-5D-3L in Jordan	11
The attractiveness of jobs in the German care sector: results of a factorial survey	11
Pharmacy cost groups for the German morbidity-based risk compensation scheme	11
Does chronic disease coverage for outpatient care affect healthcare utilization and expenditures in China? Evidence from an administrative claim dataset	11
Preferences for COVID-19 epidemic control measures among French adults: a discrete choice experiment	11
Does medial tourism promote growth in healthcare sector?	11
Do mobile hospital teams in residential aged care facilities increase health care efficiency: an evaluation of French residential care policy	11
Changes in spending, quality indicators, and provider experiences following the introduction of a population-based payment model in dutch primary care: a mixed methods evaluation	10
Work ethics, stay-at-home measures and COVID-19 diffusion	10
A comprehensive review of official discount rates in guidelines of health economic evaluations over time: the trends and roots	10
Estimating QALYs in adults with cerebral palsy: mapping the San Martin scale to the EQ-5D-5L for economic evaluation	10
Scales and size-quality outcomes in adult learning disability residential care: evidence from the UK	9
Significant healthcare burden and life cost of spinal muscular atrophy: real-world data	9
Modeling the potential efficiency of a blood biomarker-based tool to guide pre-hospital thrombolytic therapy in stroke patients	9
Self-interest, positional concerns and distributional considerations in healthcare preferences	9
Determinants of willingness to pay for health services: a systematic review of contingent valuation studies	9
Do we care about high-cost patients? Estimating the savings on health spending by integrated care	9

Validation of the PAM-13 instrument in the Hungarian general population 40 years old and above	9
Assessment of health state utilities associated with adult and pediatric acid sphingomyelinase deficiency (ASMD)	9
Optimising the impact of COVID-19 vaccination on mortality and hospitalisations using an individual additive risk measuring approach based on a risk adjustment scheme	9
Alcohol prices, the April effect, and the environment, in violence-related injury in England and Wales	9
The ACA Medicaid expansions and abortion rates among young adults	9
Tenders for generics and biosimilars: a challenging purchasing policy	9
Cost-effectiveness of two online interventions supporting self-care for eczema for parents/carers and young people	9
Survival analysis of cancer patients in Portugal following the reference centre model implementation	9
Costs of productivity loss up to two years after ischaemic stroke	8
Recovery of suspended reimbursements of high-cost drugs subjected to monitoring registries and negotiated agreements (MEAs): a tool for governance and clinical appropriateness in the Italian reality	8
How are patient inputs considered in HTA? A thematic document analysis of NICE ultra-rare disease appraisals	8
Challenges for health systems seeking to embrace virtual health care for population health	8
Personnel shortages and the provision of long-term care: an empirical analysis of German nursing homes	8
Obtaining preference scores for an abbreviated self-completion version of the Teen-Addiction Severity Index (ASC T-ASI) to value therapy outcomes of systemic family interventions: a discrete choice ex	8
Healthcare costs of diabetic foot disease in Italy: estimates for event and state costs	8
Economics of hypothalamic obesity in patients with craniopharyngioma and other rare sellar/suprasellar tumors	8
Economic evaluation on dental caries preventive interventions for Australian children using a priority-setting approach	8
The pass-through of excise taxes to market prices of heated tobacco products (HTPs) and cigarettes: a cross-country analysis	8
Cost-utility of cochlear implantation in single-sided deafness and asymmetric hearing loss: results of a randomized controlled trial	8
Supply-side solutions targeting demand-side characteristics: causal effects of a chronic disease management program on adherence and health outcomes	7
Referring physicians' intention to use hospital report cards for hospital referral purposes in the presence or absence of patient-reported outcomes: a randomized trial	7
Modeling European health systems: a theoretical exercise	7
Assessing Taiwan’s pay-for-performance program for diabetes care: a cost–benefit net value approach	7
Seeking efficiency gains outside drugs and diagnostics	7
The link between physician motivation and care	7
Trends and drivers of pharmaceutical expenditures from systemic anti-cancer therapy	7
The health and long-term care costs in the last year of life in The Netherlands	7
Inpatient care utilisation and expenditure associated with objective physical activity: econometric analysis of the UK Biobank	7
Health state utilities associated with X-linked retinitis pigmentosa (XLRP)	7
Does diagnostic testing always decrease antibiotics prescriptions?	7
Unravelling heterogeneity in efficiency measurements: a case study of public hospitals in Spain	7
Psychometric performance of proxy-reported EQ-5D youth version 5-level (EQ-5D-Y-5L) in comparison with three-level (EQ-5D-Y-3L) in children and adolescents with scoliosis	7
Disclosing the ‘Big C’: what does cancer survivorship signal to employers?	7
Does health technology assessment compromise access to pharmaceuticals?	7
One week versus three to five weeks of plaster cast immobilization for nonreduced distal radius fractures, a cost effectiveness analysis embedded in a stepped wedge cluster randomized controlled trial	6
A critical review of the use of R2 in risk equalization research	6
Cost–utility analysis of risk-reducing strategies to prevent breast and ovarian cancer in BRCA-mutation carriers in Switzerland	6
A hearing bolt-on item increased the measurement properties of the EQ-5D-5L in a community-based hearing loss screening program	6
The societal cost of ‘unwanted’ loneliness in Spain	6
Long-term costs associated with healthcare use of people with cancer in Scotland	6
Impact of the introduction of the AMNOG law on launch delays of new drugs in Germany: a comment	6
The performance of the EQ-HWB-S as a measure of quality-of-life of caregivers in families that have experienced adverse events	6
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy	6
Generating EQ-5D-3L health utility scores from the Edinburgh Postnatal Depression Scale: a perinatal mapping study	6
Obesity and metabolic state are associated with increased healthcare resource and medication use and costs: a Finnish population-based study	6
Comparing EQ-5D-5L, PROPr, SF-6D and TTO utilities in patients with chronic skin diseases	6
Time preferences and COVID-19 vaccination uptake	6
The effect of displaying laboratory test prices on physicians’ ordering behaviour: a systematic review of European studies	6
Cost-effectiveness of the MitraClip device in German heart failure patients with secondary mitral regurgitation	6
Total costs of different lines of treatment in diffuse large B-cell lymphoma in Denmark – a real-world data analysis	5
Validity and responsiveness of EQ-5D-Y in children with haematological malignancies and their caregivers	5
Assessing the relation between financial performance and long-term bank loan interest rates for healthcare providers in the Netherlands: a panel data analysis	5
The effect of telephone health coaching and remote exercise monitoring for peripheral artery disease (TeGeCoach) on health care cost and utilization: results of a randomized controlled trial	5
A novel mathematical model for prioritization of individuals to receive vaccine considering governmental health protocols	5
Valuation of EQ-5D-5L health states from cancer patients’ perspective: a feasibility study	5
Critical issues with methods and results interpretation at validating the EQ-5D-5L and QLU-C10D utilities in gastric cancer patients	5
Breaking the habit: a systematic review of the cost-effectiveness of non-pharmacological and combined interventions for smoking cessation in Europe	5
Modelling decay in effectiveness for evaluation of behaviour change interventions: a tutorial for public health economists	5
Cost-effectiveness analysis of the covered endovascular reconstruction of the aortic bifurcation versus kissing stents and open surgical repair for the treatment of aorto-iliac occlusive disease	5
Were we happy and we didn’t know it? A subjective dynamic and financial assessment pre-, during and post-COVID-19	5
Does opt-out legislation crowd out living organ donations? A cross-country study	5
Comparison of four approaches in eliciting health state utilities with SF-6Dv2	5
A systematic review of the cost-effectiveness of interventions to increase cervical cancer screening among underserved women in Europe	5
Informal care at old age at home and in nursing homes: determinants and economic value	5
On absolute socioeconomic health inequality comparisons	5
Cost-effectiveness and cost-utility analysis of a nurse-led, transitional care model to improve care coordination for patients with cardiovascular diseases: results from the “Cardiolotse” study	5
Translating the EORTC CAT core and the QLQ-C30 to the EQ-5D-5L in patients with metastatic breast cancer: A comparison of direct and indirect mapping algorithms	5
Risk, time preferences, trustworthiness and COVID-19 preventive behavior: evidence from France	5
Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease	5
EQ-5D-5L Portuguese population norms	5
Resource utilization and disaggregated cost analysis of bariatric surgery in the Australian public healthcare system	5
Health technology assessment criteria as drivers of coverage with managed entry agreements: a case study of cancer medicines in four countries	5
Making the rules make sense: valuation of constrained resources	5
A cost-of-illness study of Behçet syndrome in Italy	5
New evidence on supplier-induced demand in China’s public tertiary hospitals: is the cost of hospitalization higher in the off-season?	5
Correction: Lifetime direct healthcare costs of treating colorectal cancer: a systematic review	5
Estimating surgery, radiotherapy and systemic anti-cancer therapy treatment costs for cancer patients by stage at diagnosis	4
The remarkably frequent use of EQ-5D in non-economic research	4
Measuring the acceptability of EQ-5D-3L health states for different ages: a new adaptive survey methodology	4
Variation in patient-reported outcomes after total hip replacement across ten high-volume hospitals in Germany: results from a multicenter, prospective, longitudinal Cohort Study	4

Loss aversion in EQ-5D-Y-3L: does it explain differences in willingness to trade-off life years in adults and children?	4
Does compulsory schooling affect health? Evidence from ambulatory claims data	4
Future medical and non-medical costs and their impact on the cost-effectiveness of life-prolonging interventions: a comparison of five European countries	4
A state-level analysis of macro-level factors associated with hospital readmissions	4
Comparison of EQ-5D-5L and EORTC QLU-C10D utilities in gastric cancer patients	4
Cost-effectiveness of 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer: preplanned cost-effectiveness analysis of the JFMC37-0801 study	4
Out-of-pocket costs sustained in the last 12 months by cancer patients: an Italian survey-based study on individual expenses between 2017 and 2018	4
Public versus private healthcare systems in the OECD area– a broad evaluation of performance	4
The handling of missing data in trial-based economic evaluations: should data be multiply imputed prior to longitudinal linear mixed-model analyses?	4
Routine measurement in low back pain; towards a pragmatic patient-reported productivity cost outcome measurement using the institute for medical technology assessment productivity cost questionnaire	4
Early start of anti-dementia medication is associated with lower health and social care costs in Alzheimer´s patients: a Finnish nationwide register study	4
Decision thresholds with genetic testing	4
Complexities of health and acceptance of electronic health records for the Austrian elderly population	4
Willingness to pay for measures to increase use of active school transport	4
Does a free maternity policy in Kenya work? Impact and cost–benefit consideration based on demographic health survey data	4
Migration-related determinants of health-care service utilization among persons with a direct migration background in Germany: an exploratory study based on the German Socio-Economic Panel (SOEP)	4
Shaping a suitable EU HTA dossier template: why the German template is not fit for purpose	4
Comparison of the EQ-5D-Y and the CHU-9D instruments in a general child population based on self-reports and proxy-reports	4
Financial risk allocation and provider incentives in hospital–insurer contracts in The Netherlands	4
Population normative data for OxCAP-MH capability scores	4
Age, morbidity, and time to death: End-of-life expenditures on health care for the young-old population	3
How do family doctors respond to reduced waiting times for cancer diagnosis in secondary care?	3
The effects of patient cost-sharing on health expenditure and health among older people: Heterogeneity across income groups	3
Dividend policy issues in the European pharmaceutical industry: new empirical evidence	3
Nexus among health expenditures, ICTs and sustainable economic growth: Insights from South Asian Nationals health and economic issues	3
Probabilistic microsimulation to examine the cost-effectiveness of hospital admission screening strategies for carbapenemase-producing enterobacteriaceae (CPE) in the United Kingdom	3
Cost-effectiveness of Mavacamten for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy using a French healthcare perspective	3
Vaccination or NPI? A conjoint analysis of German citizens' preferences in the context of the COVID-19 pandemic	3
Value drivers of development stage biopharma companies	3
Are costs derived from diagnosis-related groups suitable for use in economic evaluations? A comparison across nine European countries in the European Healthcare and Social Cost Database	3
Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France	3
“COVID-19 and income inequality in OECD countries:” A methodological comment	3
Impact of Long COVID on productivity and informal caregiving	3
Costs associated with insufficient physical activity in Germany: cross-sectional results from the baseline examination of the German national cohort (NAKO)	3
Is there a link between health care utilisation and subjective well-being? An exploratory study among older Danes	3
Lifetime direct healthcare costs of treating colorectal cancer: a systematic review	3
Nonprofit behavior altered by monetary donations: evidence from the U.S. hospice industry	3
The economic burden of idiopathic pulmonary fibrosis in Australia: a cost of illness study	3
Estimating the willingness-to-pay to avoid the consequences of foodborne illnesses: a discrete choice experiment	3
Cost-effectiveness analysis of procalcitonin and lung ultrasonography guided antibiotic prescriptions in primary care	3
Comparing the measurement properties of the EQ-5D-5 L, SF-6Dv2, QLU-C10D and FACT-8D among survivors of classical Hodgkin’s lymphoma	3
Ageing and health care expenditures: the importance of age per se, steepening of the individual-level expenditure curve, and the role of morbidity	3
The EORTC QLU-C10D: the Hong Kong valuation study	3
Economic and human burden attributable to antimicrobial resistance in Spain: a holistic macro-estimation of costs	3
Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L descriptive systems and utilities in atopic dermatitis	3
Test-retest reliability of the Online Elicitation of Personal Utility Functions (OPUF) approach for valuing the EQ-HWB-S	3
Exploring non-iterative time trade-off methods for valuation of EQ-5D-5L health states	3
The economic burden of asthma in Italy: evaluating the potential impact of different treatments in adult patients with severe eosinophilic asthma	3
Cancer-specific utility: clinical validation of the EORTC QLU-C10D in patients with glioblastoma	3
The impact of parastomal hernia on quality of life using data from the CIPHER prospective cohort study	3
Towards compatibility of EUnetHTA JCA methodology and German HTA: a systematic comparison and recommendations from an industry perspective	3
Does uptake of specialty care affect HRQoL development in COPD patients beneficially? A difference-in-difference analysis linking claims and survey data	3
Completing the time trade-off with respondents who are older, in poorer health or with an immigrant background in an EQ-5D-5L valuation study	3
The EQ-5D-3L valuation study for Bermuda: using an on-line EQ-VT protocol	3
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations	3
TF-TAVI and SAVR post-procedural complications in Germany 2021/2022 – impact on healthcare resource consumption	3
Population preferences for non-pharmaceutical interventions to control the SARS-CoV-2 pandemic: trade-offs among public health, individual rights, and economics	3
United Kingdom value set for the functional assessment of cancer therapy eight dimension (FACT-8D) preference-based quality of life instrument	3
The common interests of health protection and the economy: evidence from scenario calculations of COVID-19 containment policies	3
Population norms for the EQ-5D-5L for Hungary: comparison of online surveys and computer assisted personal interviews	3
Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin’s lymphoma	3
Health shocks and health behavior: a long-term perspective	3
Short- and intermediate-term impact of DTC telemedicine consultations on subsequent healthcare consumption	3
Out-of-pocket expenses of patients with inflammatory bowel disease: a comparison of patient-reported outcomes across 12 European countries	3
Does the abolition of copayment increase ambulatory care utilization?: a quasi-experimental study in Germany	3
What remains after the money ends? Evidence on whether admission reductions continued following the largest health and social care integration programme in England	3
Catastrophic household expenditure associated with out-of-pocket payments for dental healthcare in Spain	2
Trends in physical and mental health needs across generations in Australia	2
The added value of the cognition, dining, gastrointestinal problems, sleep and tiredness bolt-on dimensions to the EQ-5D-5L in patients with coeliac disease	2
Pembrolizumab vs. chemotherapy in the first-line setting of PD-L1 ≥ 50% metastatic non-small cell lung cancer: a real-world cost-effectiveness analysis	2
Cost-effectiveness of TAVI in the United Kingdom: a long-term analysis based on 4-year data from the Evolut Low Risk Trial	2
Time and lexicographic preferences in the valuation of EQ-5D-Y with time trade-off methodology	2
Do institutions matter for citizens’ health status? Empirical evidence from Italy	2
Cost-effectiveness of dialectical behavioural therapy versus treatment as usual for autism with suicidal behaviours: single-blind randomised controlled trial	2
A Spanish value set for the SF-6D based on the SF-12 v1	2
Value appropriation in hepatitis C	2
Monetary value of health—a practical decision-making framework combining equity considerations and WTP	2
The causal effect of early retirement on medication use across sex and occupation: evidence from Danish administrative data	2
Cost-effectiveness of the MitraClip device in secondary mitral regurgitation: comment upon the article by Estler et al.	2
Bayesian cost-effectiveness analysis of Whole genome sequencing versus Whole exome sequencing in a pediatric population with suspected genetic disorders	2
Exploring the social value and design preferences for a home-based dementia community program in Australia	2
Measuring EQ-5D-5L utility values in parents who have experienced perinatal death	2
Country-level effects of diagnosis-related groups: evidence from Germany’s comprehensive reform of hospital payments	2
Unravelling risk selection in Spanish general government employee mutual funds: evidence from cancer hospitalizations in the public health network	2
Does timing matter? The role of health information shocks in measuring willingness to pay	2
Mapping functions for the PHQ-9 and GAD-7 to generate EQ-5D-3L for economic evaluation	2
Does competition improve hospital performance: a DEA based evaluation from the Netherlands	2
Using machine learning to estimate health spillover effects	2
Changes in disposable income of Polish households and growing trends in alcohol mortality	2
Health-related quality of life assessed by EQ-5D-5L and its determinants among rural adults: result from the Henan rural cohort study	2
Willingness to pay for health gains from an international integrated early warning system for infectious disease outbreaks	2
To what extent does the use of crosswalks instead of EQ-5D value sets impact reimbursement decisions?: a simulation study	2
Driving time drives the hospital choice: choice models for pelvic organ prolapse surgery in Italy	2
The economic burden of mental disorders: results from the Netherlands mental health survey and incidence study-2	2
Cost effectiveness of a GP delivered medication review to reduce polypharmacy and potentially inappropriate prescribing in older patients with multimorbidity in Irish primary care: the SPPiRE cluster	2